Literature DB >> 11378568

Autoimmune lymphoproliferative syndrome type III, an indefinite disorder.

J van der Werff ten Bosch1, J Otten, K Thielemans.   

Abstract

Autoimmune Lymphoproliferative Syndrome (ALPS) is a childhood disorder characterized by chronic nonmalignant lymphoproliferation and autoimmunity. Although the pathogenesis is not fully understood, deficient Fas mediated apoptosis appears to be an important factor. This deficiency can be caused by a mutation of the APTI gene (ALPS type Ia), of the FasL gene (ALPS type Ib), or of the Caspase-10 gene (ALPS type II). In one sub population of patients, no mutations have been identified as yet (ALPS type III). According to published data, the latter group is much smaller than the group of patients with ALPS type Ia. However, because of the variability of the clinical presentation and the absence of a known genetic defect, this disease is difficult to diagnose, the more so as few data have been reported on these patients. Thus, ALPS type III could be more common than believed until now. In this review we provide evidence for this hypothesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11378568     DOI: 10.3109/10428190109060341

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  5 in total

Review 1.  How I treat autoimmune lymphoproliferative syndrome.

Authors:  V Koneti Rao; João Bosco Oliveira
Journal:  Blood       Date:  2011-09-01       Impact factor: 22.113

2.  Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome.

Authors:  Kennichi C Dowdell; Julie E Niemela; Susan Price; Joie Davis; Ronald L Hornung; João Bosco Oliveira; Jennifer M Puck; Elaine S Jaffe; Stefania Pittaluga; Jeffrey I Cohen; Thomas A Fleisher; V Koneti Rao
Journal:  Blood       Date:  2010-04-01       Impact factor: 22.113

3.  Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS).

Authors:  V Koneti Rao; Susan Price; Katie Perkins; Patricia Aldridge; Jean Tretler; Joie Davis; Janet K Dale; Fred Gill; Kip R Hartman; Linda C Stork; David J Gnarra; Lakshmanan Krishnamurti; Peter E Newburger; Jennifer Puck; Thomas Fleisher
Journal:  Pediatr Blood Cancer       Date:  2009-07       Impact factor: 3.167

4.  Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS).

Authors:  Kennichi C Dowdell; Lesley Pesnicak; Victoria Hoffmann; Kenneth Steadman; Alan T Remaley; Jeffrey I Cohen; Stephen E Straus; V Koneti Rao
Journal:  Exp Hematol       Date:  2009-02-12       Impact factor: 3.084

Review 5.  Dual Role of Fas/FasL-Mediated Signal in Peripheral Immune Tolerance.

Authors:  Akiko Yamada; Rieko Arakaki; Masako Saito; Yasusei Kudo; Naozumi Ishimaru
Journal:  Front Immunol       Date:  2017-04-05       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.